Allspring Global Investments
SMMT icon

Allspring Global Investments’s Summit Therapeutics SMMT Stock Holding History

Allspring Global Investments’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-33,915
Closed -$83K – 2907
2022
Q1 		$83K Buy
33,915
+16,527
+95% +$41.7K ﹤0.01% 2783
2021
Q4 		$46K Buy
+17,388
New +$83.6K ﹤0.01% 2857

Other funds holding SMMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Allspring Global Investments's SMMT Position: Q2 2022 in Review

Allspring Global Investments sold out of Summit Therapeutics (SMMT) in Q2 2022, closing a stake of 33,915 shares — an estimated $83K sold.

Allspring Global Investments first reported a position in SMMT in Q4 2021 and held it in 2 quarters. The position peaked at $83K in Q1 2022. 45 funds tracked by Wall St. Rank hold SMMT as of Q2 2022.

  • Allspring Global Investments reported no remaining Summit Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 33,915 Summit Therapeutics shares in Q2 2022, an estimated $83K.
  • Allspring Global Investments first reported a position in Summit Therapeutics in Q4 2021 and held it in 2 quarters.
  • Allspring Global Investments's Summit Therapeutics position peaked at $83K in Q1 2022.
  • 45 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.